Term
|
Definition
Anticholinergic reduces ACh influence to level compatible with the reduced DA influence |
|
|
Term
|
Definition
Anticholinergic reduces ACh influence to level compatible with the reduced DA influence |
|
|
Term
|
Definition
Anticholinergic reduces ACh influence to level compatible with the reduced DA influence |
|
|
Term
|
Definition
Anticholinergic reduces ACh influence to level compatible with the reduced DA influence |
|
|
Term
|
Definition
immediate precursor of dopamine |
|
|
Term
|
Definition
cofactor for L-aromatic amino acid decarboxylase and can increase the peripheral decarboxylation of L-DOPA to dopamine. Increased dopamine means it cant cross BBB so the 1% before will become less |
|
|
Term
|
Definition
DA receptor antagonists and can prevent the antiparkin-son effects of DA derived from L-DOPA. |
|
|
Term
|
Definition
dopa decarboxylase inhibitor that inhibits conversion of L-DOPA to DA quaternary ammonium structure prevents passage across BBB |
|
|
Term
|
Definition
MAOB inhibitor that prevents oxidative deamination of only dopamine |
|
|
Term
|
Definition
MAOB inhibitor that prevents oxidative deamination of only dopamine |
|
|
Term
|
Definition
COMT inhibitors that prevent peripheral metabolism of L-DOPA hepatotoxicity |
|
|
Term
|
Definition
COMT inhibitors that prevent peripheral metabolism of L-DOPA |
|
|
Term
carbidopa/L-DOPA/ entcapone (Stalevo®) |
|
Definition
COMT inhibitors that prevent peripheral metabolism of L-DOPA |
|
|
Term
|
Definition
ergot agonists at D1 used as adjunct therapy to reduce dose of L-DOPA due to additive antiparkinson effect. |
|
|
Term
|
Definition
ergot agonists at D1/D2 receptors used as adjunct therapy to reduce dose of L-DOPA due to additive antiparkinson effect. |
|
|
Term
|
Definition
parkinson monotherapy non-ergot agonists at D2 excreted unchanged in urine |
|
|
Term
|
Definition
parkinson monotherapy non-ergot agonists at D3 metabolized by liver |
|
|
Term
|
Definition
parkinson monotherapy 24-hour continuous delivery system |
|
|
Term
|
Definition
Parkinson monothrapy indirect dopamine receptor agonist releases dopamine from nerve endings and/or blocks dopamine reuptake into nerve endings in cases of mild parkinsonism antiviral drug for influenza A2 |
|
|
Term
|
Definition
huntingtons disease clinical manifestatiion sudden, quick non-rhthymic movements of heads and limbs |
|
|
Term
|
Definition
huntingtons disease clinical manifestatiion writhing of limbs and face |
|
|
Term
|
Definition
– involuntary hurling, irregular, huntingtons disease clinical manifestatiion frequently violent movements of the shoulder and arm while the patient is awake |
|
|
Term
|
Definition
Huntingtons Treatment reserpine-like DA depleting agent,. Reserpine blocks vmat, which transports epi,NE,and DA to vesicle so it can be released in the synapse. |
|
|
Term
|
Definition
Huntingtons Treatment DA receptor antagonist |
|
|
Term
|
Definition
Huntingtons Treatment DA stabilizer in clinical trials, not known how |
|
|
Term
|
Definition
Huntingtons Treatment AChE-inhibitor (experimental) |
|
|
Term
|
Definition
extremely withdrawn, negative and isolated in catatonic stupor and/or overexcitement, repetitious sounds or movements in catatonic excitement |
|
|
Term
|
Definition
most common)— very suspicious of others, delusions of persecution, auditory hallucinations, delusions of grandeur |
|
|
Term
disorganized (hebephrenic) schizophrenia |
|
Definition
—(everything they do is unintelligent) verbally incoherent, illogical thinking, flat or inappropriate moods and emotions, hallucinations usually not present |
|
|
Term
|
Definition
no overt signs of schizophrenia but lacking motivation and interest in day-to-day living |
|
|
Term
undifferentiated schizophrenia |
|
Definition
patient fails to meet the criteria for the other subtypes but clearly suffers from this mental disorder |
|
|
Term
|
Definition
(DMPEA) from urine samples of schizo people |
|
|
Term
|
Definition
projections to nucleus accumbens, limbic system and frontal cortex |
|
|
Term
|
Definition
motivation, pleasure, concentration and working memory |
|
|
Term
|
Definition
substantial nigra projections to corpus striatum extrapyramidal motor control and cognition |
|
|
Term
tuberoinfundibular pathway |
|
Definition
arcuate nucleus projections to pituitary gland neuroendocrine regulation connects to pituitary and releast pituitary hormones, thus dopamine controls release of these hormones. |
|
|
Term
|
Definition
• subthalamis projections to hypothalamus and amygdala sexual arousal |
|
|
Term
|
Definition
excessive DA neurotransmission due to excessive DA synthesis/release and/or DA receptor supersensitivity |
|
|
Term
|
Definition
|
|
Term
|
Definition
antipsychotic or neuroleptic drugs |
|
|
Term
|
Definition
Phenothiazines multiple receptor blockade & inhibition of neuronal reuptake conventional neuroleptic Highest in OH |
|
|
Term
|
Definition
Phenothiazines multiple receptor blockade & inhibition of neuronal reuptake conventional neuroleptic Only high in AP and EPS |
|
|
Term
|
Definition
Phenothiazines multiple receptor blockade & inhibition of neuronal reuptake conventional neuroleptic Highest in AC Lowest in EPS |
|
|
Term
|
Definition
Butyrophenones multiple receptor blockade & inhibition of neuronal reuptake conventional neuroleptic Only high in AP and EPS |
|
|
Term
|
Definition
Atypical (unconventional) neuroleptics No OH or EPS Lowest in AP with quetiapine agranulocytosis |
|
|
Term
|
Definition
Atypical (unconventional) neuroleptics reversible blockade of DA and 5HT2A receptors 5HT2A > D2 receptor specificity 5HT1A agonist action |
|
|
Term
|
Definition
Atypical (unconventional) neuroleptics reversible blockade of DA and 5HT2A receptors 5HT2A > D2 receptor specificity 5HT1A agonist action |
|
|
Term
|
Definition
Atypical (unconventional) neuroleptics reversible blockade of DA and 5HT2A receptors 5HT2A > D2 receptor specificity 5HT1A agonist action Lowest in NEG control Lowest in AP with clozapine |
|
|
Term
|
Definition
Atypical (unconventional) neuroleptics reversible blockade of DA and 5HT2A receptors 5HT2A > D2 receptor specificity 5HT1A agonist action Lowest in sedation and weight gain |
|
|
Term
|
Definition
Atypical (unconventional) neuroleptics reversible blockade of DA and 5HT2A receptors 5HT2A > D2 receptor specificity 5HT1A agonist action Lowest in sedation and weight gain |
|
|
Term
|
Definition
Dementia Treatment treatment of mild-to-moderate Alzheimer’s cholinesterase-inhibitors — increase in synaptic levels of acetylcholine |
|
|
Term
|
Definition
Dementia Treatment used for mild-to-severe Alzheimer’s cholinesterase-inhibitors — increase in synaptic levels of acetylcholine |
|
|
Term
|
Definition
Dementia Treatment treatment of mild-to-moderate Alzheimer’s cholinesterase-inhibitors — increase in synaptic levels of acetylcholine |
|
|
Term
|
Definition
prevention of glutamate excitotoxicity treatment of moderate-to-severe Alzheimer’s |
|
|
Term
|
Definition
(not approved) antioxidants—neuroprotective effect against oxidative stress |
|
|
Term
|
Definition
Older anxiolytic non-barbiturate, non-benzodiazepine |
|
|
Term
|
Definition
Older anxiolytic meprobamate-like (non-barbiturate, non-benzodiazepine |
|
|
Term
|
Definition
Older anxiolytic meprobamate-like (non-barbiturate, non-benzodiazepine |
|
|
Term
|
Definition
Older anxiolytic meprobamate-like (non-barbiturate, non-benzodiazepine |
|
|
Term
|
Definition
Long acting Benzodiazepines |
|
|
Term
|
Definition
Long acting Benzodiazepines |
|
|
Term
|
Definition
short acting Benzodiazepines |
|
|
Term
|
Definition
short acting Benzodiazepines |
|
|
Term
|
Definition
short acting Benzodiazepines |
|
|
Term
|
Definition
Benzodiazepine antagonist, blocking BZD agonists and inverse agonists |
|
|
Term
Drugs that increase BZD hepatic metabolism |
|
Definition
chronic alcohol, barbiturates, phenytoin or carbamazepine (usually the oxidized bzd) |
|
|
Term
Drugs that decrease BZD hepatic metabolism |
|
Definition
valproic acid, propranolol |
|
|
Term
BZD hepatic metabolism decreased by estrogen-dominant oral contraceptives |
|
Definition
oxidized benzodiazepines (lorazepam, alprazolam) |
|
|
Term
BZD hepatic metabolism increased by estrogen-dominant oral contraceptives |
|
Definition
glucuronidation of conjugated diazepam, oxazepam and temazepam |
|
|
Term
|
Definition
prolongation of long- but not short-acting BZs |
|
|
Term
|
Definition
azaspirodecanedione
agonist at presynaptic 5-HT1A receptors |
|
|
Term
|
Definition
2-3 week state where you are extremely depressed but it is self limiting and lasts only for a few weeks |
|
|
Term
|
Definition
mild state of depression, that lasts for 2 years |
|
|
Term
|
Definition
2 amine tricyclics NE>5-HT Least weight gain Worst are in sex |
|
|
Term
|
Definition
2 amine tricyclics NE>5-HT Least weigth gain Worst are in sex |
|
|
Term
|
Definition
tetracyclic NE>5-HT Only one with on sex dysfunction high weight and sedation |
|
|
Term
|
Definition
3 amine tricyclics (high on all effects) 5-HT>NE |
|
|
Term
|
Definition
3 amine tricyclics (high on all effects) 5-HT>NE |
|
|
Term
|
Definition
SSRI's (selective serotonin reuptake-inhibitors |
|
|
Term
|
Definition
SSRI's (selective serotonin reuptake-inhibitors Only one with mild effect on everything. |
|
|
Term
|
Definition
SSRI's (selective serotonin reuptake-inhibitors |
|
|
Term
|
Definition
SSRI's (selective serotonin reuptake-inhibitors |
|
|
Term
|
Definition
SSRI's (selective serotonin reuptake-inhibitors Least sexual dysfunction |
|
|
Term
|
Definition
|
|
Term
|
Definition
Newer atypical antidepressants NDRI blocks DA reuptake >> NE reuptake No side effects |
|
|
Term
|
Definition
Newer atypical antidepressants SARI blockade of 5HT2A receptors plus less potent serotonin reuptake Highest OH and sedation |
|
|
Term
|
Definition
Newer atypical antidepressants SARI blockade of 5HT2A receptors plus less potent serotonin reuptake hepatotoxic |
|
|
Term
|
Definition
Newer atypical antidepressants SNRI inhibition of 5HT and NE reuptake High in sexual dysfunction |
|
|
Term
|
Definition
Newer atypical antidepressants NaSSA blockade of 2 and 5HT2A heteroreceptors to disinhibit NE and 5HT neuronal release High in sexual dysfunction and sedation |
|
|
Term
|
Definition
irreversible and non-selective MAO-inhibitors |
|
|
Term
|
Definition
irreversible and non-selective MAO-inhibitors hepatotoxicity |
|
|
Term
|
Definition
reversible inhibitors of MAOA |
|
|
Term
|
Definition
reversible inhibitors of MAOA |
|
|
Term
|
Definition
reversible inhibitors of MAOA |
|
|
Term
|
Definition
paradoxical CNS excitation when combined with MAOI |
|
|
Term
|
Definition
drug actions: unknown(not for depressant, can help in mania and bipolar) |
|
|
Term
|
Definition
other FDA-approved drugs with antimanic activity |
|
|
Term
|
Definition
other FDA-approved drugs with antimanic activity |
|
|
Term
|
Definition
other FDA-approved drugs with antimanic activity |
|
|
Term
|
Definition
other FDA-approved drugs with antimanic activity |
|
|
Term
|
Definition
other FDA-approved drugs with antimanic activity |
|
|
Term
fluoxetine/olanzapine Symbyax®) |
|
Definition
other FDA-approved drugs with antimanic activity |
|
|
Term
|
Definition
unlabelled use in manic syndrome stimulation of presynaptic adenosine receptors NE release |
|
|
Term
|
Definition
amphetamine derivatives more potent centrally |
|
|
Term
|
Definition
amphetamine derivatives more potent centrally |
|
|
Term
|
Definition
amphetamine derivatives more potent centrally prodrug |
|
|
Term
|
Definition
amphetamine derivatives. more potent peripherally |
|
|
Term
|
Definition
amphetamine derivatives Benzedrine®, Adderall®) |
|
|
Term
|
Definition
amphetamine derivatives more similar to dextro) |
|
|
Term
|
Definition
non-amphetamine stimulants |
|
|
Term
|
Definition
non-amphetamine stimulants |
|
|
Term
|
Definition
phenylethylamine anorexiants (all withdrawn by manufacturers) |
|
|
Term
|
Definition
phenylethylamine anorexiants (all withdrawn by manufacturers) |
|
|
Term
inhibition of lateral hypothalamic feeding center |
|
Definition
|
|
Term
stimulation of ventromedial hypothalamic satiety center via 5HT release |
|
Definition
|
|
Term
|
Definition
new drug for narcolepsy with fewer side effects (less excessive mood change, less insomnia, less abuse potential), 1B adrenergic receptor effects and may also affect GABA, glutaminergic and serotonergic synapses |
|
|
Term
|
Definition
non-stimulant ( non-controlled) approved for the treatment of ADHD in children, adolescents, and adults selective norepinephrine reuptake inhibitor |
|
|
Term
|
Definition
most important active ingredient of cannabis. |
|
|
Term
most important active ingredient of cannabis. |
|
Definition
combination of dried resin extract and compressed flowers and contains 5-15% 9-THC. |
|
|
Term
|
Definition
extracted from marihuana or hashish and may be 30-80% THC |
|
|
Term
|
Definition
Cannabinoid Receptors found in the brain and other tissues, blood vessels, cardiac tissue |
|
|
Term
|
Definition
Cannabinoid Receptors part of the immune system, immunosuppressant |
|
|
Term
|
Definition
endocannabinoids (derived from arachidonic acid acts on CB1 and CB2 receptor |
|
|
Term
|
Definition
endocannabinoids (derived from arachidonic acid acts on CB1 receptors |
|
|
Term
|
Definition
endocannabinoids (derived from arachidonic acid acts on CB1 receptors |
|
|
Term
|
Definition
|
|
Term
|
Definition
synthetic nabilone , an analog of dronabinol |
|
|
Term
|
Definition
withdrawn from market inverse agonist/antagonist at CB1 receptor causes reduction in appetite increased risk of diabetes 2 and dyslipidemia |
|
|
Term
|
Definition
Psychedelics Excessive DA = psychotic behavior |
|
|
Term
lysergic acid diethylamide (LSD) |
|
Definition
Psychedelics Works by Activating Serotonin Psychotropic properties |
|
|
Term
|
Definition
Psychedelics periodical change of the behavior of elephant bulls |
|
|
Term
|
Definition
unique effect of LSD occurs when a person can see smells, hear colors, over stimulation |
|
|
Term
|
Definition
antidotal therapy for pschedelics |
|
|
Term
|
Definition
dissociatives MOST DANGEROUS Acure toxicity, combativeness, catatonia, convulsions, coma |
|
|
Term
|
Definition
dissociatives reduction in pain but can’t figure out where it’s coming from. Hurt or not Block NMDA receptor |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
pattern of PCP abuse first phase |
|
Definition
acute toxicity – 4C’s combativeness, catatonia, convulsions and coma |
|
|
Term
pattern of PCP abuse second phase |
|
Definition
toxic psychosis visual and auditory delusions, paranoia and agitation |
|
|
Term
pattern of PCP abuse third phase |
|
Definition
drug-induced schizophrenia |
|
|
Term
pattern of PCP abuse fourth phase |
|
Definition
drug-induced depression suicidal tendencies, mental dysfunction (last for months |
|
|